AstraZeneca Exanta Liver Toxicity Outweighs Benefit – FDA Advisory Cmte.

Cardiovascular & Renal Drugs Advisory Committee votes against recommending approval for all three indications AstraZeneca is seeking for the anticoagulant. The firm’s proposed risk management plan did not seem adequate to prevent severe liver injury, committee members agree.